Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the …

…, GS Day, M Sager, J Stevens, A Rae-Grant - Neurology, 2018 - AAN Enterprises
Rae-Grant: analysis or interpretation of data, drafting/revising the manuscript, critical revision
of … Rae-Grant report no disclosures relevant to the manuscript. Go to Neurology.org/N for full …

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo …

…, J Oger, J Antel, P Conlon, L Steinman, A Rae-Grant… - Nature medicine, 2000 - nature.com
In this ‘double-blind’, randomized, placebo-controlled phase II trial, we compared an altered
peptide ligand of myelin basic protein with placebo, evaluating their safety and influence on …

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination …

A Rae-Grant, GS Day, RA Marrie, A Rabinstein… - Neurology, 2018 - AAN Enterprises
Rae-Grant receives royalties from 2 textbooks he has published, 1 on neurology and 1 on
multiple sclerosis (MS); organizes and receives honoraria for grand rounds and neurology …

A clinical approach to diagnosis of autoimmune encephalitis

…, E Lancaster, F Leypoldt, H Prüss, A Rae-Grant… - The lancet …, 2016 - thelancet.com
Encephalitis is a severe inflammatory disorder of the brain with many possible causes and a
complex differential diagnosis. Advances in autoimmune encephalitis research in the past …

Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American …

…, YT So, F Cantor, DR Cornblath, A Rae-Grant - Neurology, 2011 - AAN Enterprises
Objective: To reassess the role of plasmapheresis in the treatment of neurologic disorders.
Methods: We evaluated the available evidence based on a structured literature review for …

Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management

…, Y Li, M Matiello, AM Morse, A Rae-Grant… - Journal of Neurology …, 2021 - jnnp.bmj.com
The objective of this paper is to evaluate available evidence for each step in autoimmune
encephalitis management and provide expert opinion when evidence is lacking. The paper …

Diagnosis and treatment of multiple sclerosis: a review

MP McGinley, CH Goldschmidt, AD Rae-Grant - Jama, 2021 - jamanetwork.com
Importance Multiple sclerosis (MS) is an autoimmune-mediated neurodegenerative disease
of the central nervous system characterized by inflammatory demyelination with axonal …

Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders [RETIRED] Report of the Therapeutics and Technology …

HS Patwa, V Chaudhry, H Katzberg, AD Rae-Grant… - Neurology, 2012 - AAN Enterprises
Objective: To assess the evidence for the efficacy of IV immunoglobulin (IVIg) to treat
neuromuscular disorders. Methods: The MEDLINE, Web of Science, and EMBASE databases were …

Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN guideline subcommittee

…, WS David, C Armon, BA Perkins, V Bril, A Rae-Grant… - Neurology, 2022 - AAN Enterprises
Objective To update the 2011 American Academy of Neurology (AAN) guideline on the
treatment of painful diabetic neuropathy (PDN) with a focus on topical and oral medications and …

Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and …

A Rae-Grant, GS Day, RA Marrie, A Rabinstein… - Neurology, 2018 - AAN Enterprises
Objective To review evidence on starting, switching, and stopping disease-modifying
therapies (DMTs) for multiple sclerosis (MS) in clinically isolated syndrome (CIS), relapsing-…